News & Updates
Filter by Specialty:
Hydroxychloroquine use does not increase risk of heart failure in RA patients
Use of hydroxychloroquine (HCQ) does not contribute to the development of heart failure (HF) in patients with rheumatoid arthritis (RA), a study has shown.
Hydroxychloroquine use does not increase risk of heart failure in RA patients
15 Oct 2021
Methotrexate–leflunomide combo safe in rheumatoid arthritis
Methotrexate (MTX) plus leflunomide (LEF) demonstrates a relatively good safety profile overall compared with the combination of MTX and sulfasalazine (SSZ) and strategies involving advanced therapies in rheumatoid arthritis (RA), reports a study.
Methotrexate–leflunomide combo safe in rheumatoid arthritis
15 Oct 2021
Baricitinib: A potential treatment for alopecia areata?
Baricitinib, an oral, selective Janus kinase (JAK)1/JAK2 inhibitor, may help improve hair growth in patients with severe alopecia areata, according to results from the phase III BRAVE-AA1 and BRAVE-AA2 trials.
Baricitinib: A potential treatment for alopecia areata?
14 Oct 2021
Second bDMARD after failure of non-TNFi biologic in RA shows modest drug survival, response
A recent study has shown modest drug survival and primary response of a second biologic disease-modifying antirheumatic drug (bDMARD) in patients with rheumatoid arthritis (RA) switching due to failure of a nontumour necrosis factor inhibitor (non-TNFi) bDMARD as the first agent.
Second bDMARD after failure of non-TNFi biologic in RA shows modest drug survival, response
14 Oct 2021
Smoking reduces effect of methotrexate-based treatment in RA patients
Current smoking reduces the response of patients with early rheumatoid arthritis (RA) to methotrexate (MTX) in a dose-responsive manner, regardless of concomitant prednisone use, a recent study has found.
Smoking reduces effect of methotrexate-based treatment in RA patients
14 Oct 2021
Lenzilumab reduces likelihood of survival without ventilation in COVID-19 patients
In hospitalized COVID-19 patients, treatment with the novel GM-CSF* neutralizing monoclonal antibody lenzilumab led to a significant improvement in survival without invasive mechanical ventilation (SWOV), findings from the phase III LIVE-AIR study suggest.